Aussie company's killer CAR deal

Melbourne-based clinical stage cell therapy company Chimeric Therapeutics has exercised an exclusive option with a US university for a new platform technology that can develop next-generation, off-the-shelf Natural Killer (NK) and CAR NK products.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here